Joseph Kauer

427 total citations
23 papers, 196 citations indexed

About

Joseph Kauer is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Joseph Kauer has authored 23 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 9 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Joseph Kauer's work include Acute Myeloid Leukemia Research (8 papers), Multiple Myeloma Research and Treatments (7 papers) and CAR-T cell therapy research (6 papers). Joseph Kauer is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Multiple Myeloma Research and Treatments (7 papers) and CAR-T cell therapy research (6 papers). Joseph Kauer collaborates with scholars based in Germany, United States and Austria. Joseph Kauer's co-authors include Jonas S. Heitmann, Helmut R. Salih, Melanie Märklin, Gundram Jung, Clemens Hinterleitner, Latifa Zekri, Hans‐Georg Rammensee, Malte Roerden, Ilona Hagelstein and Stefanie Müller and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and Biotechnology and Bioengineering.

In The Last Decade

Joseph Kauer

22 papers receiving 196 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph Kauer Germany 8 107 82 65 58 44 23 196
Simon Steiger Germany 5 146 1.4× 82 1.0× 96 1.5× 110 1.9× 52 1.2× 6 242
Mahan Moshir Belgium 6 99 0.9× 95 1.2× 65 1.0× 35 0.6× 39 0.9× 11 192
Jing Christine Ye United States 7 139 1.3× 61 0.7× 89 1.4× 82 1.4× 44 1.0× 20 262
Kristi Elkins United Kingdom 5 174 1.6× 42 0.5× 103 1.6× 51 0.9× 68 1.5× 8 273
Emine Gulsen Gunes United States 8 103 1.0× 132 1.6× 85 1.3× 52 0.9× 16 0.4× 15 243
Yadira M. Soto-Feliciano United States 4 75 0.7× 85 1.0× 122 1.9× 33 0.6× 26 0.6× 7 240
Heather Ogana United States 7 66 0.6× 34 0.4× 66 1.0× 87 1.5× 19 0.4× 16 204
Ilona Hagelstein Germany 8 150 1.4× 157 1.9× 45 0.7× 33 0.6× 29 0.7× 26 224
Yu Abe Japan 9 169 1.6× 186 2.3× 102 1.6× 99 1.7× 33 0.8× 27 326
Torben Altmann Germany 5 190 1.8× 131 1.6× 56 0.9× 78 1.3× 66 1.5× 8 253

Countries citing papers authored by Joseph Kauer

Since Specialization
Citations

This map shows the geographic impact of Joseph Kauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Kauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Kauer more than expected).

Fields of papers citing papers by Joseph Kauer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Kauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Kauer. The network helps show where Joseph Kauer may publish in the future.

Co-authorship network of co-authors of Joseph Kauer

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Kauer. A scholar is included among the top collaborators of Joseph Kauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Kauer. Joseph Kauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kauer, Joseph, et al.. (2025). Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma. Journal for ImmunoTherapy of Cancer. 13(1). e009245–e009245. 4 indexed citations
2.
Schlenk, Richard F., Jan Moritz Middeke, Stefan W. Krause, et al.. (2024). Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML. Blood Advances. 9(2). 375–385. 1 indexed citations
3.
Kauer, Joseph, Katharina Kriegsmann, Niels Weinhold, et al.. (2023). Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma. Hematological Oncology. 41(3). 453–462. 5 indexed citations
4.
Sauer, Sandra, et al.. (2023). Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients. Transfusion Medicine and Hemotherapy. 50(5). 382–395. 2 indexed citations
5.
Sauer, Sandra, Katharina Kriegsmann, Cathleen Nientiedt, et al.. (2023). Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma. Transfusion Medicine and Hemotherapy. 50(5). 371–381. 4 indexed citations
6.
7.
8.
Yurttas, Can, Markus Burkard, Alexander Tolios, et al.. (2022). Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model. Cancers. 14(5). 1158–1158. 6 indexed citations
9.
Marconato, Maddalena, Joseph Kauer, Helmut R. Salih, Melanie Märklin, & Jonas S. Heitmann. (2022). Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia. Scientific Reports. 12(1). 15856–15856. 7 indexed citations
10.
Kauer, Joseph, Melanie Märklin, Clemens Hinterleitner, et al.. (2022). BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. Journal of Cancer Research and Clinical Oncology. 148(10). 2759–2771. 2 indexed citations
11.
Märklin, Melanie, Clemens Hinterleitner, Claudia Tandler, et al.. (2022). Identification of CD105 (endoglin) as novel risk marker in CLL. Annals of Hematology. 101(4). 773–780. 3 indexed citations
12.
Ghosh, Michael, et al.. (2021). Mass spectrometry for quality control of bispecific antibodies after SDS‐PAGE in‐gel digestion. Biotechnology and Bioengineering. 118(8). 3069–3075. 3 indexed citations
13.
Hagelstein, Ilona, et al.. (2020). CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation. International Journal of Hematology. 112(1). 57–64. 4 indexed citations
14.
15.
Märklin, Melanie, Claudia Tandler, Jonas S. Heitmann, et al.. (2020). Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia. Frontiers in Immunology. 11. 1995–1995. 4 indexed citations
16.
Heitmann, Jonas S., Ilona Hagelstein, Clemens Hinterleitner, et al.. (2020). Identification of CD318 (CDCP1) as novel prognostic marker in AML. Annals of Hematology. 99(3). 477–486. 19 indexed citations
17.
Märklin, Melanie, Jonas S. Heitmann, Joseph Kauer, Stefan Wirths, & Martin Müller. (2020). Genetic loss of NFAT2 (NFATc1) impairs B cell development of B1 and B2 B cells. Cellular Immunology. 349. 104048–104048. 6 indexed citations
18.
Kauer, Joseph, Stefanie Müller, Melanie Märklin, et al.. (2020). Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. Journal for ImmunoTherapy of Cancer. 8(1). e000621–e000621. 38 indexed citations
19.
Heitmann, Jonas S., Ilona Hagelstein, Clemens Hinterleitner, et al.. (2020). Fc gamma receptor expression serves as prognostic and diagnostic factor in AML. Leukemia & lymphoma. 61(10). 2466–2474. 8 indexed citations
20.
Kauer, Joseph, Claudia Tandler, Clemens Hinterleitner, et al.. (2019). CD105 (Endoglin) as negative prognostic factor in AML. Scientific Reports. 9(1). 18337–18337. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simon Steiger Breakdown of academic impact, for papers by Mahan Moshir Breakdown of academic impact, for papers by Jing Christine Ye Breakdown of academic impact, for papers by Kristi Elkins Breakdown of academic impact, for papers by Emine Gulsen Gunes Breakdown of academic impact, for papers by Yadira M. Soto-Feliciano Breakdown of academic impact, for papers by Heather Ogana Breakdown of academic impact, for papers by Ilona Hagelstein Breakdown of academic impact, for papers by Yu Abe Breakdown of academic impact, for papers by Torben Altmann
Rankless by CCL
2026